Chinese drug firm Sinopharm finally publishes Covid-19 vaccine trial data

• Interim phase 3 results suggest two products have efficacy above 70 per cent for symptomatic cases but there is little data on elderly and vulnerable groups
• More than 200 million doses have already been administered worldwide and a vaccine made by the firm’s Beijing subsidiary has been approved by the WHO